07/11/19 -"We have made some adjustments to take into account the huge impairment and added some first costs (€120m for 2019-21) in the implementation of the €300-350m cost reduction plan to our P&L. "
Pages
57
Language
English
Published on
07/11/19
You may also be interested by these reports :
30/01/26
The decline has been due to lower earnings expectations, as outlined in the EPS section. In addition, we have applied a 10% discount to peer ...
29/01/26
Givaudan’s top-line performance was approximately in line with expectations; however, this was insufficient due to higher-than-anticipated costs. ...
28/01/26
We have revised our FY25 EPS upward, primarily reflecting management guidance pointing to higher at-equity earnings from Wintershall Dea. Our FY26 ...
28/01/26
Wacker’s preliminary FY25 results remain uninspiring, with earnings falling short of already conservative market expectations. While sales remained ...